WEINSTEIN ROBERT 4

What Happened Robert Weinstein, a director of PharmaCyte Biotech, was granted a derivative award on 2026-03-31 covering 119,170 shares. The Form 4 records the acquisition price as $0.00 (derivative award); the filing does not report a cash value or an exercise price. This was a grant/award of equity (options), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-31; Form 4 filed: 2026-04-02 (timely)
• Transaction type/code: Grant / Award (A) — derivative transaction
• Shares/units involved: 119,170 underlying shares
• Price: $0.00 reported for the award on the Form 4
• Shares owned after the transaction: Not disclosed in the filing
• Footnote: The options "shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Weinstein."

Context

• This is an equity award (options) that vests in the future rather than an immediate purchase or sale; it does not necessarily indicate a near-term market transaction.
• Because the grant vests only upon continued service to the next annual meeting, it functions as a retention/incentive award rather than an immediate liquidity event.